iRegene Therapeutics Raises 210M Yuan in Series C1 for AI-Powered Cell Therapy Platform

iRegene Therapeutics raised 210 million yuan in a Series C1 round led by Guanghe Capital and Xingze Capital.

The funding will help advance clinical programs, improve its AI-based chemical induction platform, and expand manufacturing.

The company also plans to support global trials and partnerships for its cell therapy pipeline.

Its programs target hard-to-treat diseases including Parkinson's, multiple system atrophy, and vision loss.